Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review

Sijongesonke Peter, Sibusiso Alven, Rejoice Bethusile Maseko*, Blessing Atim Aderibigbe*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

40 Citations (Scopus)


The scarcity of novel and effective therapeutics for the treatment of cancer is a pressing and alarming issue that needs to be prioritized. The number of cancer cases and deaths are increasing at a rapid rate worldwide. Doxorubicin, an anticancer agent, is currently used to treat several types of cancer. It disrupts myriad processes such as histone eviction, ceramide overproduction, DNA-adduct formation, reactive oxygen species generation, Ca2+, and iron hemostasis regulation. However, its use is limited by factors such as drug resistance, toxicity, and congestive heart failure reported in some patients. The combination of doxorubicin with other chemotherapeutic agents has been reported as an effective treatment option for cancer with few side effects. Thus, the hybridization of doxorubicin and other chemotherapeutic drugs is regarded as a promising approach that can lead to effective anticancer agents. This review gives an update on hybrid compounds containing the scaffolds of doxorubicin and its derivatives with potent chemotherapeutic effects.

Original languageEnglish
Article number4478
Issue number14
Publication statusPublished - Jul 2022


  • cancer
  • chemotherapeutic drugs
  • doxorubicin
  • drug resistance
  • drug toxicity
  • hybrid compounds


Dive into the research topics of 'Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review'. Together they form a unique fingerprint.

Cite this